このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

InBodyLtd 将来の成長

Future 基準チェック /26

InBodyLtd利益と収益がそれぞれ年間14.8%と10.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に15.4% 12.8%なると予測されています。

主要情報

14.8%

収益成長率

12.8%

EPS成長率

Medical Equipment 収益成長	35.4%
収益成長率	10.6%
将来の株主資本利益率	15.4%
アナリストカバレッジ	Low
最終更新日	14 Jun 2024

今後の成長に関する最新情報

Recent updates

InBodyLtd (KOSDAQ:041830) Could Be Struggling To Allocate Capital

Apr 12

Why Dividend Hunters Love InBody Co.,Ltd (KOSDAQ:041830)

Mar 25

Can InBody Co.,Ltd (KOSDAQ:041830) Performance Keep Up Given Its Mixed Bag Of Fundamentals?

Mar 08

Do Insiders Own Lots Of Shares In InBody Co.,Ltd (KOSDAQ:041830)?

Feb 18

How Much Did InBodyLtd's(KOSDAQ:041830) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 31

Has InBodyLtd (KOSDAQ:041830) Got What It Takes To Become A Multi-Bagger?

Jan 11

InBody Co., Ltd. (KOSDAQ:041830) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Dec 24

Why Dividend Hunters Love InBody Co., Ltd. (KOSDAQ:041830)

Dec 17

InBody Co., Ltd.'s (KOSDAQ:041830) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Dec 02

Do Institutions Own InBody Co., Ltd. (KOSDAQ:041830) Shares?

Nov 17

業績と収益の成長予測

KOSDAQ:A041830 - アナリストの将来予測と過去の財務データ ( )KRW Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	231,200	51,100	39,100	55,100	1
12/31/2025	217,600	48,200	40,633	49,100	3
12/31/2024	193,300	40,300	31,500	43,000	1
3/31/2024	175,754	35,172	28,471	36,566	N/A
12/31/2023	170,351	36,723	31,058	38,686	N/A
9/30/2023	171,523	35,376	31,552	37,222	N/A
6/30/2023	165,663	32,528	35,212	41,247	N/A
3/31/2023	164,431	34,112	29,908	35,998	N/A
12/31/2022	160,004	33,816	24,402	30,419	N/A
9/30/2022	154,925	36,465	12,603	26,992	N/A
6/30/2022	149,075	34,329	11,047	24,743	N/A
3/31/2022	143,399	34,038	15,509	27,809	N/A
12/31/2021	137,837	34,033	18,368	30,351	N/A
9/30/2021	128,762	31,729	33,120	34,657	N/A
6/30/2021	125,036	30,556	34,879	36,687	N/A
3/31/2021	112,334	22,620	28,008	29,932	N/A
12/31/2020	107,122	17,518	26,581	28,500	N/A
9/30/2020	109,493	14,492	18,023	20,897	N/A
6/30/2020	107,806	13,559	15,980	18,609	N/A
3/31/2020	116,393	19,969	20,210	22,925	N/A
12/31/2019	117,059	20,428	20,974	24,206	N/A
9/30/2019	113,404	21,164	23,353	26,767	N/A
6/30/2019	110,791	22,187	19,624	25,403	N/A
3/31/2019	106,381	21,398	-16,094	25,190	N/A
12/31/2018	99,635	19,671	-23,234	17,705	N/A
9/30/2018	98,925	21,918	-25,462	14,546	N/A
6/30/2018	98,352	21,686	-24,373	13,837	N/A
3/31/2018	95,337	20,570	8,577	13,077	N/A
12/31/2017	93,254	19,322	N/A	18,576	N/A
9/30/2017	86,462	17,506	N/A	20,600	N/A
6/30/2017	80,006	14,859	N/A	16,750	N/A
3/31/2017	76,806	14,574	N/A	19,353	N/A
12/31/2016	79,848	16,987	N/A	18,238	N/A
9/30/2016	79,954	16,853	N/A	14,624	N/A
6/30/2016	80,356	19,165	N/A	16,789	N/A
3/31/2016	76,561	18,359	N/A	14,651	N/A
12/31/2015	68,949	17,311	N/A	11,179	N/A
9/30/2015	61,594	13,802	N/A	11,679	N/A
6/30/2015	54,675	10,615	N/A	10,386	N/A
3/31/2015	52,053	9,302	N/A	8,039	N/A
12/31/2014	48,940	8,879	N/A	10,259	N/A
9/30/2014	45,498	9,160	N/A	9,515	N/A
6/30/2014	42,966	8,362	N/A	9,828	N/A
3/31/2014	39,831	7,060	N/A	7,904	N/A
12/31/2013	36,787	6,194	N/A	6,995	N/A
9/30/2013	35,676	5,545	N/A	7,613	N/A
6/30/2013	34,602	5,357	N/A	5,319	N/A

アナリストによる今後の成長予測

収入対貯蓄率: A041830の予測収益成長率 (年間14.8% ) は貯蓄率 ( 2.5% ) を上回っています。

収益対市場: A041830の収益 ( 14.8% ) KR市場 ( 28.9% ) よりも低い成長が予測されています。

高成長収益: A041830の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: A041830の収益 ( 10.6% ) KR市場 ( 10.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: A041830の収益 ( 10.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: A041830の自己資本利益率は、3年後には低くなると予測されています ( 15.4 %)。

InBodyLtd 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased to ₩34,000

Recent updates

Full year 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of ₩300 per share at 1.2% yield

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 18%

Upcoming dividend of ₩200 per share

No independent directors

InBody Releases BPBIO 220 and BPBIO 250

No independent directors

Inbody Co.,Ltd Releases New Bwa 2.0 Body Water Analyzer

Upcoming dividend of ₩140 per share

Price target increased to ₩34,000

Investor sentiment improved over the past week

InBodyLtd (KOSDAQ:041830) Could Be Struggling To Allocate Capital

Why Dividend Hunters Love InBody Co.,Ltd (KOSDAQ:041830)

Full year 2020 earnings released: EPS ₩1,335 (vs ₩1,532 in FY 2019)

Can InBody Co.,Ltd (KOSDAQ:041830) Performance Keep Up Given Its Mixed Bag Of Fundamentals?

Do Insiders Own Lots Of Shares In InBody Co.,Ltd (KOSDAQ:041830)?

New 90-day high: ₩19,600

How Much Did InBodyLtd's(KOSDAQ:041830) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day high: ₩19,200

Has InBodyLtd (KOSDAQ:041830) Got What It Takes To Become A Multi-Bagger?

New 90-day high: ₩18,500

InBody Co., Ltd. (KOSDAQ:041830) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Upcoming Dividend of ₩140 Per Share

Why Dividend Hunters Love InBody Co., Ltd. (KOSDAQ:041830)

New 90-day high: ₩18,300

InBody Co., Ltd.'s (KOSDAQ:041830) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Do Institutions Own InBody Co., Ltd. (KOSDAQ:041830) Shares?

New 90-day high: ₩17,450

New 90-day low: ₩15,300

New 90-day low - ₩15,350

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘